Literature DB >> 11419578

Characteristics and trends of newly identified HIV infections among incarcerated populations: CDC HIV voluntary counseling, testing, and referral system, 1992-1998.

K M Sabin1, R L Frey, R Horsley, S M Greby.   

Abstract

Inmate contact with the correctional health care system provides public health professionals an opportunity to offer HIV screening to a population that might prove difficult to reach otherwise. We report on publicly funded human immunodeficiency virus (HIV) voluntary counseling, testing, and referral (VCTR) services provided to incarcerated persons in the United States. Incarcerated persons seeking VCTR services received pretest counseling and gave a blood specimen for HIV antibody testing. Specimens were considered positive if the enzyme immunoassays were repeatedly reactive and the Western blot or immunofluorescent assay was reactive. Demographics, HIV risk information, and laboratory test results were collected from each test episode. Additional counseling sessions provided more data. From 1992 to 1998, there were 527,937 records available from correctional facilities from 48 project areas; 484,277 records included a test result and 459,155 (87.0%) tests came with complete data. Overall, 3.4% (16,797) of all tests were reactive for HIV antibodies. Of reactive tests accompanied by self-reports of previous HIV test results (15,888), previous test results were 44% positive, 23% negative, 6% inconclusive or unspecified, and 27% no previous test. This indicates that 56% of positive tests were newly identified. During the study period, the number of tests per year increased three-fold. Testing increased among all racial/ethnic groups and both sexes. The largest increase was for heterosexuals who reported no other risk, followed by persons with a sex partner at risk. Overall, the greatest number of tests was reported for injection drug users (IDUs) (128,262), followed by men who have sex with men (MSM) (19,928); however, episodes for MSM doubled during the study, while for IDUs, they increased 74%. The absolute number of HIV-positive (HIV+) tests increased 50%; however, the percentage of all tests that were HIV+ decreased nearly 50% due to the increased number of tests performed. HIV+ tests fell 50% among blacks (7.6% to 3.7%), Hispanics (6.7% to 2.5%), and males (5.1% to 2.5%); 33% among females (4.5% to 3.1%); 95% among IDUs (8.6% to 4.4%); and 64% among MSM (19.3% to 11.8%). Among HIV+ episodes, those for IDUs dropped from 61.5% to 36.6%, while episodes for heterosexuals with no reported risk factor increased from 4.3% to 18.2%. The use of VCTR services by incarcerated persons rose steadily from 1992 to 1998, and 56% of HIV+ tests were newly identified. High numbers of tests that recorded risk behaviors for contracting HIV indicate that correctional facilities provide an important access point for prevention efforts.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11419578      PMCID: PMC3456357          DOI: 10.1093/jurban/78.2.241

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  17 in total

1.  The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants.

Authors:  D Vlahov; J C Anthony; A Munoz; J Margolick; K E Nelson; D D Celentano; L Solomon; B F Polk
Journal:  NIDA Res Monogr       Date:  1991

2.  Temporal trends of human immunodeficiency virus type 1 (HIV-1) infection among inmates entering a statewide prison system, 1985-1987.

Authors:  D Vlahov; F Brewer; A Muñoz; D Hall; E Taylor; B F Polk
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

3.  Incidence of hepatitis B in the penitentiary of New Mexico.

Authors:  H F Hull; L H Lyons; J M Mann; S C Hadler; R Steece; M R Skeels
Journal:  Am J Public Health       Date:  1985-10       Impact factor: 9.308

4.  Anonymous or confidential HIV counseling and voluntary testing in federally funded testing sites--United States, 1995-1997.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1999-06-25       Impact factor: 17.586

5.  Prevalence and incidence of HIV among incarcerated and reincarcerated women in Rhode Island.

Authors:  J D Rich; B P Dickinson; G Macalino; T P Flanigan; C W Towe; A Spaulding; D Vlahov
Journal:  J Acquir Immune Defic Syndr       Date:  1999-10-01       Impact factor: 3.731

6.  Seroconversion to human immunodeficiency virus in prison inmates.

Authors:  C R Horsburgh; J Q Jarvis; T McArther; T Ignacio; P Stock
Journal:  Am J Public Health       Date:  1990-02       Impact factor: 9.308

7.  Voluntary testing for human immunodeficiency virus (HIV) in a prison population with a high prevalence of HIV.

Authors:  C Behrendt; N Kendig; C Dambita; J Horman; J Lawlor; D Vlahov
Journal:  Am J Epidemiol       Date:  1994-05-01       Impact factor: 4.897

8.  Seroepidemiology of hepatitis B in Tennessee prisoners.

Authors:  M D Decker; W K Vaughn; J S Brodie; R H Hutcheson; W Schaffner
Journal:  J Infect Dis       Date:  1984-09       Impact factor: 5.226

9.  Hepatitis B in Wisconsin male prisoners: considerations for serologic screening and vaccination.

Authors:  R F Anda; S B Perlman; D J D'Alessio; J P Davis; V N Dodson
Journal:  Am J Public Health       Date:  1985-10       Impact factor: 9.308

10.  Prevalence of antibody to HIV-1 among entrants to US correctional facilities.

Authors:  D Vlahov; T F Brewer; K G Castro; J P Narkunas; M E Salive; J Ullrich; A Muñoz
Journal:  JAMA       Date:  1991-03-06       Impact factor: 56.272

View more
  12 in total

1.  Making the case for health interventions in correctional facilities.

Authors:  T M Hammett
Journal:  J Urban Health       Date:  2001-06       Impact factor: 3.671

Review 2.  Jails, prisons, and the health of urban populations: a review of the impact of the correctional system on community health.

Authors:  N Freudenberg
Journal:  J Urban Health       Date:  2001-06       Impact factor: 3.671

3.  Newly identified HIV infections in correctional facilities, United States, 2007.

Authors:  Michelle VanHandel; John F Beltrami; Robin J MacGowan; Craig B Borkowf; Andrew D Margolis
Journal:  Am J Public Health       Date:  2012-03-08       Impact factor: 9.308

4.  From corrections to communities as an HIV priority.

Authors:  David Vlahov; Sara Putnam
Journal:  J Urban Health       Date:  2006-05       Impact factor: 3.671

Review 5.  The HIV Care Cascade Before, During, and After Incarceration: A Systematic Review and Data Synthesis.

Authors:  Princess A Iroh; Helen Mayo; Ank E Nijhawan
Journal:  Am J Public Health       Date:  2015-05-14       Impact factor: 9.308

6.  HIV counseling and testing among Hispanics at CDC-funded sites in the United States, 2007.

Authors:  Denise Duran; Hussain R Usman; John Beltrami; Maria E Alvarez; Linda Valleroy; Cynthia M Lyles
Journal:  Am J Public Health       Date:  2010-02-10       Impact factor: 9.308

7.  Effectiveness of a Peer Navigation Intervention to Sustain Viral Suppression Among HIV-Positive Men and Transgender Women Released From Jail: The LINK LA Randomized Clinical Trial.

Authors:  William E Cunningham; Robert E Weiss; Terry Nakazono; Mark A Malek; Steve J Shoptaw; Susan L Ettner; Nina T Harawa
Journal:  JAMA Intern Med       Date:  2018-04-01       Impact factor: 21.873

8.  HIV risk behavior and internalizing/externalizing psychopathology among adolescents in court-ordered treatment.

Authors:  Robert C McMahon; Evan T Stanforth; Jessy G Dévieux; Michèle Jean-Gilles
Journal:  Am J Drug Alcohol Abuse       Date:  2016-02-10       Impact factor: 3.829

9.  Black Americans and Incarceration: A Neglected Public Health Opportunity for HIV Risk Reduction.

Authors:  Tawandra L Rowell-Cunsolo; Nabila El-Bassel; Carl L Hart
Journal:  J Health Care Poor Underserved       Date:  2016

10.  Treating drug abuse and addiction in the criminal justice system: improving public health and safety.

Authors:  Redonna K Chandler; Bennett W Fletcher; Nora D Volkow
Journal:  JAMA       Date:  2009-01-14       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.